Co-Authors
This is a "connection" page, showing publications co-authored by Peter Kalivas and Robert Malcolm.
Connection Strength
0.831
-
N-acetylcysteine for the treatment of comorbid alcohol use disorder and posttraumatic stress disorder: Design and methodology of a randomized clinical trial. Contemp Clin Trials. 2020 04; 91:105961.
Score: 0.185
-
A Double-Blind, Randomized, Controlled Pilot Trial of N-Acetylcysteine in Veterans With Posttraumatic Stress Disorder and Substance Use Disorders. J Clin Psychiatry. 2016 Nov; 77(11):e1439-e1446.
Score: 0.147
-
A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. Am J Addict. 2013 Sep-Oct; 22(5):443-52.
Score: 0.116
-
Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav. 2012 Feb; 100(4):801-10.
Score: 0.100
-
The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry. 2009 May 15; 65(10):841-5.
Score: 0.085
-
Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry. 2007 Jul; 164(7):1115-7.
Score: 0.077
-
An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30; 31(2):389-94.
Score: 0.074
-
Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs. 2014 Feb; 28(2):95-106.
Score: 0.030
-
Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict. 2006 Jan-Feb; 15(1):105-10.
Score: 0.017